Omada Health (NASDAQ:OMDA) Given New $18.00 Price Target at BMO Capital Markets

Omada Health (NASDAQ:OMDA) had its target price reduced by BMO Capital Markets from $27.00 to $18.00 in a research note published on Friday morning,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

Several other equities analysts have also weighed in on OMDA. The Goldman Sachs Group restated a “buy” rating and issued a $26.00 price objective on shares of Omada Health in a report on Friday, January 16th. Barclays lowered their target price on shares of Omada Health from $22.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday. Morgan Stanley cut their price target on Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday. Evercore raised their price target on Omada Health from $27.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, Wells Fargo & Company initiated coverage on Omada Health in a research note on Thursday, January 8th. They set an “equal weight” rating and a $17.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Omada Health presently has an average rating of “Moderate Buy” and a consensus target price of $22.90.

Omada Health Stock Performance

NASDAQ:OMDA traded up $0.45 on Friday, hitting $14.05. 5,381,314 shares of the stock were exchanged, compared to its average volume of 1,317,712. Omada Health has a 52 week low of $10.28 and a 52 week high of $28.40. The stock has a market capitalization of $813.64 million and a price-to-earnings ratio of -56.20. The company’s 50-day moving average price is $14.03 and its 200 day moving average price is $18.68.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, March 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.12. The business had revenue of $75.85 million during the quarter.

Insider Buying and Selling at Omada Health

In other news, President Wei-Li Shao sold 5,618 shares of the stock in a transaction on Monday, December 29th. The shares were sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the sale, the president owned 69,079 shares of the company’s stock, valued at $1,114,244.27. This represents a 7.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sean P. Duffy sold 230,479 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $15.60, for a total value of $3,595,472.40. Following the transaction, the chief executive officer owned 126,644 shares of the company’s stock, valued at approximately $1,975,646.40. This trade represents a 64.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 276,893 shares of company stock valued at $4,336,787 in the last three months.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas acquired a new position in shares of Omada Health during the 2nd quarter worth about $640,000. Geode Capital Management LLC acquired a new stake in shares of Omada Health in the second quarter valued at about $637,000. Franklin Resources Inc. acquired a new stake in shares of Omada Health in the second quarter valued at about $2,695,000. Eisler Capital Management Ltd. bought a new stake in Omada Health during the second quarter worth about $545,000. Finally, XTX Topco Ltd acquired a new position in Omada Health during the second quarter valued at approximately $414,000.

Key Headlines Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.